Definitive Healthcare Q2 Revenue Misses, Guides Below Street
DH is trading near its 52-week low of $0.62 (13% above the low).
Summary
Definitive Healthcare reported Q2 revenue of $55.2M, a 9% decline year-over-year and slightly below the $55.48M consensus. The company posted a net loss of $7.45M. Q3 revenue guidance of $54M-$55M and full-year guidance of $220M-$222M both came in below Street expectations. On a positive note, net dollar retention improved for a second straight quarter and the company launched a new AI-powered healthcare intelligence platform. The stock, trading near $0.70, faces delisting risk after a Nasdaq notice in June for failing to meet the minimum bid price requirement. The 10-Q shows goodwill fully impaired to zero from $197.2M at year-end, with total assets falling to $496.8M from $735.5M. Cash and equivalents rose to $170.9M from $163.6M.
Updated with an SEC 10-Q filing · What changed
Updates
· SEC 10-Q — The 10-Q shows goodwill fully impaired to zero from $197.2M at year-end, with total assets falling to $496.8M from $735.5M. Cash and equivalents rose to $170.9M from $163.6M.
At the time of this announcement, DH was trading at $0.70 on NASDAQ in the Technology sector, with a market capitalization of approximately $100.4M. The 52-week trading range was $0.62 to $4.70. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.